ArticleBMC neurology2025
New-onset drug-resistant epilepsy in type 1 diabetes mellitus patient following COVID-19 vaccination: suspicious for autoimmune pathogenesis.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing Understanding of Epilepsy and Type 1 Diabetes Mellitus: A Global Perspective on Research Trends and Future Directions.Journal of diabetes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWithin the spectrum of epilepsies, autoimmune-associated epilepsy (AAE) reflects the complexity of its presentations including refractory seizures along with cognitive decline and behavioral or psychiatric dysfunction. The suspicion of autoimmune epilepsy is heightened in individuals who have a pre-existing autoimmune condition, such as type 1 diabetes mellitus (T1DM). This report details a case of autoimmune epilepsy associated with Glutamic acid decarboxylase (GAD65) antibodies coexisting with T1DM. CASE DESCRIPTION: The subject of this clinical case is a 48-year-old male with a history of T1DM and hypothyroidism, who exhibited new behavioral alterations and refractory focal seizures two weeks post- COVID-19 vaccination. Initially, his symptoms were misinterpreted as panic attacks. Months later, these attacks were diagnosed as focal epilepsy after multiple evaluations including, interictal and ictal electroencephalograms, brain Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET). The patient underwent several trials of antiseizure medications and their combinations, yet no significant effects were observed. The Antibody Prevalence in Epilepsy and Encephalopathy (APE2) score was determined, yielding a result of 4, and the presence of elevated Glutamic acid decarboxylase (GAD65) antibodies in the serum led to a confirmed diagnosis of autoimmune encephalitis (AAE). Following a course of intravenous immunoglobulin, no notable improvement was recorded; however, subsequent corticosteroid therapy, accompanied by rigorous blood glucose monitoring, resulted in a positive but partial reduction in seizure frequency. The patient was planned to start on long-term use of azathioprine.
conclusionThis case exemplifies the diagnostic challenges inherent in autoimmune-associated epilepsy and underscores the necessity for prompt intervention. Glutamic acid decarboxylase (GAD65) antibody-associated autoimmune epilepsy should be suspected in adult-onset temporal lobe epilepsy with co-morbid type 1 DM with early initiation of immune therapy for better clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.